Adult neurogenesis is responsible for the continuous generation and integration of new neurons in existing neural networks. These neurons are derived from multipotent neural stem cells (NSCs) residing in specialized neurogenic niches. The subventricular zone (SVZ) is the largest of these niches in the adult brain and is capable of generating at least 30,000 new neurons in rodents that then migrate through the rostral migratory stream (RMS) to integrate into networks in the olfactory bulb (OB) (Lois and AlvarezBuylla, 1994) . One of the characteristics of tissue stem cell niches is the presence of quiescent stem cells, but unfortunately these quiescent cells are usually difficult to study since attempts to culture them or isolate them usually lead to activation. The study by Codega et al. (2014) in this issue of Neuron provides new insights into the nature of quiescent NSCs in the SVZ and also important tools that will facilitate future studies of these cells.
In the SVZ, type B1 cells make up the primary NSC population; they divide to either self-renew or produce a secondary progenitor population, the intermediate progenitors (transit-amplifying or type C cells) that generate various neuronal subtypes destined for the OB, as well as progenitors that generate glial cell types (see Figure 1) . Type B1 cells express glial fibrillary acidic protein (GFAP + ) and maintain a bipolar morphology, with specialized apical processes that extend to receive signals from the CSF in the lateral ventricles and basal processes that maintain contact with blood vessels (Merkle et al., 2004; Mirzadeh et al., 2008; Shen et al., 2008; Tavazoie et al., 2008 (Doetsch et al., 1999; Morshead et al., 1994; Pastrana et al., 2009) . The characterization of the structure of GFAP + type B1 cells, along with lineage-tracing studies, established that type B1 NSCs in the SVZ are the source of postnatally generated glial and neuronal cell subtypes. However, the relative contributions of active NSCs (aNSCs) versus quiescent NSCs (qNSCs) in the replenishment of type B1 cells and the production of specific neuronal and glial cell subtypes under normal and pathological states have not been elucidated. In addition, direct observations examining the potential precursor-product transitions between qNSCs and aNSCs have been lacking, with most understanding of their relationship being inferred. This is largely due to the lack of markers distinguishing qNSCs from aNSCs hampering examination of the lineage potentials and regenerative capacities of the heterogeneous population of type B1 cells in the SVZ.
In this issue of Neuron, Codega et al. (2014) utilize a unique combination of markers to isolate and purify qNSCs and aNSCs from the mouse SVZ. Building on previous findings that a subset of purified CD133-positive (CD133 + ) cells from the SVZ is capable of generating neurons in vivo and neurospheres in vitro (Coskun et al., 2008) , as well as coexpressing GFAP (Beckervordersandforth et al., 2010; Mirzadeh et al., 2008) , Codega et al. (2014) postulated and found that cells expressing GFAP (labeled using the transgenic mouse line GFAP::GFP in which GFP is under the control of the GFAP promoter) and CD133 identify both qNSCs and aNSCs among SVZ cells. A key finding is the observation that EGFR, a protein expressed in aNSCs (Pastrana et al., 2009) [Carlé n et al., 2009; Coskun et al., 2008] ) to examine the regenerative properties of qNSCs in vivo. This was accomplished by utilizing an inducible Cre transgenic mouse line carrying a reporter transgene, tdTomato (GFAP::CreERT2;CAG::tdTomato). In this experiment, GFAP-derived SVZ cells were labeled by administration of tamoxifen for 10 days, followed by a 10-day infusion of Ara-C to eliminate all dividing cells. Codega et al. (2014) find that many of the tdTomato+ cells in the SVZ are eliminated after Ara-C infusion and that the remaining tdTomato+ cells do not express Nestin. However, 6 days after Ara-C removal, fractions of tdTomato+ cells began to express Nestin, and/or doublecortin, a marker for neuroblasts, implying that the remaining tdTomato+ cells are regenerative, as they are able to replenish the depleted aNSC population and contribute to the production of neuronal lineages. Thus, qNSCs retain long-term neurogenic potential and begs for further investigation of the intrinsic and extrinsic events that trigger qNSCs to enter the activated state and differentiate into neuronal or glial cell lineages.
To start to address these questions, Codega et al. (2014) performed microarray analyses that will help characterize the molecular signature of qNSCs. These experiments show that factors commonly expressed by quiescent stem cell populations in tissues outside of the nervous system are also upregulated in qNSCs, including genes encoding cell surface proteins/receptors and extracellular matrix proteins. Codega et al. (2014) then went on to show that ligands for two of these differentially expressed receptors, the G protein-coupled receptors for Sphingosine-1-Phosphate (S1P) and Prostaglandin D 2 , effectively inhibit the activation of qNSCs. Notably, S1P selectively acts on qNSCs but not aNSCs, indicating that qNSCs can be specifically targeted by extrinsic factors. Since the ligands for these receptors are found in the CSF, they may be physiologic regulators of NSC quiescence. These findings, along with the observations that qNSCs are unable to form neurospheres in vitro using currently established protocols, underscore the need to further identify and characterize factors that regulate qNSCs, as well as other NSC populations, within the SVZ neurogenic niche at different phases of adult neurogenesis. It is also worth noting that an S1P agonist was recently approved as an oral treatment for multiple sclerosis (Bolli et al., 2011) . The main mechanism of action for this agent (fingolimod-trade name Gilenya) is believed to be a modulation of lymphocyte trafficking; however, it is quite possible that this agent might affect qNSC dynamics. Since fingolimod is thought of as a first in family compound with other agents in various pipelines, it is quite possible that S1P agonists and antagonists could be studied for their effects on SVZ NSCs in future studies and in disease models. Codega et al. (2014) provide a powerful method that separates two major populations of type B1 NSCs in the SVZ. Given that the SVZ is composed of molecularly heterogeneous NSCs (Giachino et al., 2014) , future experiments must determine and characterize the existence of lineage-restricted qNSCs, and how their fate potential is affected over time under homeostatic and pathological conditions. In addition to intracellular and extracellular molecular factors, it would also be interesting to examine how other cell populations within the SVZ affect the behavior and maintenance of qNSCs. Advancing our knowledge on the biology and plasticity of qNSCs is especially valuable since the adult human brain harbors largely quiescent NSC populations (van den Berge et al., 2010) . Thus, by harnessing the regenerative potential of quiescent NSCs, new approaches The subventricular zone (SVZ) of the adult brain is populated by postmitotic ependymal cells and type B1 neural stem cells (NSCs), which generate transit-amplifying progenitors that will produce neuronal or astrocytic cells. Type B1 NSCs may be quiescent (qNSCs) or activated (aNSCs). Codega et al. (2014) distinguished and isolated GFAP-positive qNSCs from aNSCs based on the differential expression of molecular factors expressed by SVZ cells. qNSCs are ciliated radial glia-like cells that express GFAP and CD133 but not EGFR or Nestin. On the other hand, aNSCs that express GFAP, CD133, EGFR, and Nestin do not have primary cilia. Both qNSC and aNSC can divide to either self-renew or generate aNSCs, which will in turn divide to generate transit-amplifying progenitors that will produce either neuroblasts destined for the olfactory bulb or astrocytic cell lineages. Both qNSCs and aNSCs respond to signals within the CSF. Codega et al. (2014) identified two CSF molecules that regulate the quiescent state: Prostaglandin D 2 (PGD2), which acts on both qNSCs and aNSCs, and Sphingosine-1-Phosphate (S1P), which acts on qNSCs.
may be developed to effectively treat neurological diseases, particularly those caused by cellular dysfunction or tissue injury.
Itch is immensely frustrating. Most studies focus on the cause of itch. In this issue of Neuron, Kardon et al. (2014) find that itch can be modulated by inhibitory neurons that produce dynorphin, an endogenous agonist of k-opioid receptors.
Scientific investigations can be likened to scratch tickets. While individual experiments that we perform may not pan out, the study by Kardon et al. (2014) in this issue of Neuron is a winner. These investigators characterize a population of spinal inhibitory neurons and demonstrate that dynorphin, released from these neurons, is a backscratcher responsible for modulating itch (Figure 1) .
Itch, also referred to as pruritus, may have evolved as a protective mechanism against threats from arthropods, but it is a prominent feature of inflammatory skin disease and ruins the lives of patients with chronic renal failure, liver disease, and certain malignancies. Its impact on quality of life is comparable to that of pain (Kini et al., 2011) . It has been suggested that itch be considered a disease (Yosipovitch, 2011) . Drugs with itch as an approved indication are limited to antihistamines and topical steroids and have limited effectiveness. It is recognized that neuromodulators can be remarkably effective in treating some itches and that scratching may provide temporary relief and feel pleasurable, suggesting that complex neurocircuitry and neuromodulatory mechanisms are involved. Accordingly, endogenous molecules may have the potential to reduce the sensation of itch.
Understanding the underlying mechanisms of itch is an intense focus of investigation. Recent advances include the identification of a series of itch-related ligands and receptors as well as peripheral neurons and spinal afferents specialized in transmitting this sensation and distinguishing it from pain (Han et al., 2013; Mishra and Hoon, 2013) . It is recognized that itch and pain are part of a complex family dynamic. A few examples are scratching, which alleviates itch but is a noxious stimulus, m-opioids, which relieve pain but induce itch, and the inhibition of glutaminergic transmission from nociceptors, which reduces pain but increases scratching (Lagerströ m et al., 2010; Liu et al., 2010) .
A key role in sensory processes has been suggested for inhibitory circuits in the spinal cord, consistent with the
